CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 910 enrolled
Drug / intervention
LCZ696 +3 moredrug
Likely dose
LCZ696 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01281306
NCT01281306Phase 2Completed
CompareCT.gov

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension

Novartis Pharmaceuticals·interventional·Posted Jan 21, 2011·Updated Jan 29, 2016

In Brief

A Phase 2 clinical trial evaluating LCZ696, Valsartan, and 2 other interventions for Systolic Hypertension. Completed, enrolled 910 participants across 90 sites in 9 countries.

Detailed Summary

The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystolic Hypertension
CountriesArgentina, Canada, Hungary, India, Romania, Slovakia, South Korea, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 21, 2011
Enrollment StartJan 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.4 years ago

Interventions

LCZ696drug

LCZ696 was supplied as tablets in blister cards in 100 mg strengths.

Valsartandrug

Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

AHU377drug

AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.

Placebodrug

Placebo was supplied as tablets in blister cards.